OncoSec Medical (NSDQ:ONCS) said yesterday that it inked a warrant exercise agreement with unnamed holders of outstanding warrants to buy up to 5.5 million shares of the company’s common stock at an exercise price of $1.69 apiece. The San Diego, Calif.-based company raised $9.3 million in gross proceeds from the exercise of the warrants, which it plans […]
Oncology
Q Biomed looks to dust off shelved cancer pain drug
Denis Corin has spent the last 13 years in the biopharmaceutical industry watching and learning from scientists and companies that fail. “I’ve seen so many promising and innovative young technologies really struggle along or die on the vine because they’re run by scientists who don’t really understanding capital raising,” he told Drug Delivery Business News. “They run […]
OncoSec Medical names new CEO | Personnel Moves – Nov. 9, 2017
OncoSec Medical (NSDQ:ONCS) announced earlier this week that the company’s co-founder, Punit Dhillon, would step down as CEO and continue to serve as president while Daniel O’Connor takes over the corner office. O’Connor joined OncoSec’s board of directors in September this year. “We are pleased to welcome Dan to OncoSec at this important time, and believe […]
Lumicell raises $21m for image-guided cancer surgery tech
Lumicell has raised $20.7 million over the past three months, according to a regulatory document filed with SEC last week. More than 20 investors have contributed to the $26.5 million equity offering, the Wellesley, Mass.-based company reported, including one investor outside of the U.S. In September, the company announced that it plans to study its […]
The 11 most innovative medical devices of 2017
The nominees for the best medical technology of 2017 were recently announced for the 11th Annual Prix Galien USA Awards. The Galien Foundation, the host of the awards, hands out the Prix Galien Award annually to examples of outstanding biomedical and technology product achievement designed to improve human condition. Before candidates can qualify for the […]
Kite wins FDA approval for first adult CAR-T cell therapy
More than a month before it was due to make a decision, the FDA yesterday approved a CAR-T cell therapy from Kite Pharma (NSDQ:KITE) – the first of its kind for adults. The therapy, which is made from a patient’s own cells, is designed to treat adults with non-Hodgkin lymphoma who have failed at least two […]
NanOlogy takes nanoparticle tech into Phase II trials
In the last two weeks, NanOlogy has launched trials evaluating its cancer-fighting paclitaxel nanoparticle suspension in patients with prostate cancer and in patients with ovarian cancer. The Texas-based company’s nanoparticle tech is based on a production process that cuts the size of chemotherapy crystals by up to 400 times, creating stable nanoparticles with increased surface […]
Researchers treat first cancer patients with BTG’s microscopic, drug-loaded beads
Researchers from the UCL Cancer Institute and BTG (LON:BTG) have started the first clinical trial of microscopic beads loaded with a targeted, cancer-fighting drug for patients with primary liver cancer or metastatic colorectal cancer. The trial is designed to evaluate the experimental therapy’s ability to deliver a precise amount of vandetanib directly to the arteries feeding […]
First patient treated with CSA Medical’s AV spray catheter
CSA Medical said today that the first patient was treated using the company’s new rapid AV spray catheter for the management of persistent symptomatic esophageal cancer and associated dysplastic Barrett’s disease. The device uses a stainless steel catheter wall to cut the time needed to deliver liquid nitrogen spray to the treatment site by 50%, […]
GE Healthcare, Blue Earth Diagnostics ink UK manufacturing deal
Blue Earth Diagnostics and GE Healthcare (NYSE:GE) said today that the group has inked a deal to establish the manufacturing of Blue Earth Diagnostic’s positron emission tomography imaging product, Axumin, in the U.K. The agreement with GE Healthcare is part of Blue Earth Diagnostics’ move towards commercializing Axumin since it won marketing authorization from the European […]